1. Home
  2. QDEL vs NBTX Comparison

QDEL vs NBTX Comparison

Compare QDEL & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo QuidelOrtho Corporation

QDEL

QuidelOrtho Corporation

HOLD

Current Price

$11.26

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Nanobiotix S.A.

NBTX

Nanobiotix S.A.

HOLD

Current Price

$48.35

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QDEL
NBTX
Founded
1979
2003
Country
United States
France
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.0B
IPO Year
2022
2018

Fundamental Metrics

Financial Performance
Metric
QDEL
NBTX
Price
$11.26
$48.35
Analyst Decision
Hold
Strong Buy
Analyst Count
4
1
Target Price
$28.25
$36.00
AVG Volume (30 Days)
2.9M
62.8K
Earning Date
05-05-2026
03-31-2026
Dividend Yield
N/A
N/A
EPS Growth
45.35
N/A
EPS
N/A
N/A
Revenue
$2,730,200,000.00
N/A
Revenue This Year
$3.51
$58.17
Revenue Next Year
$3.86
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.95
$3.64
52 Week High
$35.58
$54.74

Technical Indicators

Market Signals
Indicator
QDEL
NBTX
Relative Strength Index (RSI) 40.99 66.18
Support Level $10.86 $20.11
Resistance Level $12.85 N/A
Average True Range (ATR) 0.94 2.71
MACD 0.09 1.76
Stochastic Oscillator 48.12 71.11

Price Performance

Historical Comparison
QDEL
NBTX

About QDEL QuidelOrtho Corporation

QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.

About NBTX Nanobiotix S.A.

Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.

Share on Social Networks: